In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18F-AV-133

• DOI: 10.2967/jnumed.109.070094
• Publication Date: 2010-01-16T01:46:37Z
• Authors: Nobuyuki Okamura; Victor L. Villemagne; John Drago; Svetlana Pejoska; Rajinder K. Dhamija; Rachel S. Mulligan; Julia R. Ellis; Uwe Ackermann; Graeme O'Keefe; Gareth Jones; Hank F. Kung; Michael J. Pontec...; Daniel Skovronsky; Christopher C. Rowe
• Keywords: Vesicular monoamine transporter; Monoaminergic; Putamen; Caudate nucleus; Binding potential

PET provides a noninvasive means to evaluate the functional integrity of presynaptic monoaminergic system in living human brain. <b>Methods:</b> In this study, novel ¹⁸F-labeled tetrabenazine derivative, ¹⁸F-(+)fluoropropyldihydrotetrabenazine (¹⁸F-AV-133), was used for assessment vesicular monoamine transporters type 2 (VMAT2) 17 Parkinson disease (PD) patients and 6 healthy controls. The binding potential (BP) ¹⁸F-AV-133 calculated using Logan graphical analysis. Voxel-based volume-of-interest–based analyses BP images were performed examine brain regional reductions VMAT2 density PD. <b>Results:</b> decreased by 81% posterior putamen, 70% anterior 48% caudate nucleus PD patients. analysis demonstrated striatum mid Furthermore, BPs nuclei significantly correlated with clinical severity <b>Conclusion:</b> These findings indicate that ligand can sensitively detect terminal Studies may allow presymptomatic identification individuals disorders characterized degeneration dopaminergic nigrostriatal afferents.